RSV vaccine

Pfizer's RSV vaccine protects newborns from serious illness

Pfizer's RSV vaccine good for pregnant women This vaccine helps

protect newborns from serious illness Pfizer has announced an experimental RSV vaccine for women that has the potential

to protect babies from serious illness for up to six months after birth. In this Phase III randomized, double-blind, 

placebo-controlled study that the company believes and the gold standard of epidemiological studies,

the vaccine was found to be 82% effective in preventing diseases caused by respiratory syncytial virus, or RSV.

It was observed through vaccination to pregnant women taking the vaccine and six months after giving birth.

The report followed for a year to protect infants from the effects of the disease, some followed for two years.

It is explained that RSV is a common respiratory virus that shows symptoms like a cold. Its serious effects can lead to

 the disease bronchiolitis, inflammation of the lungs and pneumonia. This virus occurs in the US during the fall, winter and spring.

On Tuesday, Orange County and California officials also declared a health emergency amid a surge in RSV cases,

surge in RSV cases, the Los Angeles Times reported, severely limiting availability at pediatric hospitals.